Valeant ups offer for Salix, Endo throws in the towel
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals has agreed an increased all-cash offer price for Salix Pharmaceuticals of $173 per share, up from its earlier $158 offer, prompting Endo International to pull out of the bidding war for the gastro-intestinal products specialist.
You may also be interested in...
Stockwatch: Uncertainty Trumps Earnings Seasons Fundamentals
A post-US election relief rally was magnified in life science stocks last week and swept away poor third-quarter earnings results at Valeant, Endo, AstraZeneca and Impax.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.